Bi- and Tri-Specific Antibody Therapies

• 5529 · PDF LY4336619的临床前表征，一种用于治疗卵巢癌和子宫内膜癌的新型ALPPL2×CD3双特异性抗体 Preclinical characterization of LY4336619, a novel ALPPL2xCD3 bispecific antibody, for the treatment of ovarian and endometrial cancer Colleen Burns, Julie Dobkin, Kevin Lindquist, Hee Rae Shin, Cindy Nguyen, Wei Yang, Xiaodong Huang, Marie Mutryn, Whitney S. Helms, Nicholas Arce, Yvonne Mak, Alexandra Antonoplis, Amelie Forest, Abraham Abouzeid, Marta Witek, Claire F. Friedman, Zhao Hai Lu, Mohan Srinivasan, Kyla Driscoll, Andrew Hass, Omar Duramad, Rikke Holmgaard, Kristin Bedard
• 5530 · PDF M0324的抗肿瘤活性和安全性的临床前验证，一种新型MUC-1条件性CD40激动剂，及其与免疫检查点抑制剂（ICI）联合以实现选择性免疫激活 Preclinical validation of the antitumor activity and safety of M0324, a novel MUC-1 conditional CD40 agonist, and its combination with immune checkpoint inhibitors (ICIs), for selective immune activation Weixiao Sha, Jing Ni, Anika Bergmann, Nathalie Duncan, Bo Marelli, Feng Jiang, Julia Marie Mueller, Sina Junkers, Christina Hubl, Ivana Durutovic, Sonia Jaramillo, Paul D. Lyne, Laura Helming
• 5532 · PDF 靶向EGFR和HER2的双特异性抗体通过安全的CD47-SIRPA调节有效杀伤实体瘤细胞 Bispecific antibodies targeting EGFR and HER2 for effective killing of solid tumor cells via a safe CD47-SIRPA modulation Eric Hatterer, Vanessa Buatois, Alizée Viandier, Emeline Rousset, Cécile Raymond, Adeline Lesnier, Pauline Lloveras, Christelle Mougin, Ulla Ravn, Pauline Malinge, Frederic Bollin, Limin Shang, Walter Ferlin, Nicolas Fischer, Jose Saro, Krzysztof Masternak
• 5533 · PDF VISTA×MSLN双特异性抗体导向疗法作为上皮样恶性胸膜间皮瘤生物标志物指导的策略 VISTA×MSLN bispecific antibody-directed therapies as a biomarker-guided strategy for epithelioid malignant pleural mesothelioma Sang Moo Lee, Hee geon Park, Gyo-Jin Choi, Myeung Ryun Seo, Ji Eun Park, Seok Gyeong Yun, Na Eun Jeong, Soo Jin Ryu, Yeong Jeong Jeon, Yoon La Choi, Sung Youl Hong, Young Kee Shin
• 5534 · PDF INCA036873，一种首创的CD70×CD3 T细胞重定向双特异性抗体，用于治疗CD70阳性恶性肿瘤 INCA036873, a first-in-class CD70×CD3 T cell-redirecting bispecific antibody, for the treatment of CD70-positive malignancies Yao-Bin Liu, Charlie Kang, Christina Stevens, Lifeng Zhang, Daniel Merenich, Emily Ren, Chifei Sun, Lu Huo, Taylor Getty, Heather Bullins, Zhiwan Dong, Zhiying Ji, Michelle Kinder, Jun Guan, Tessa Steevels, Femke Feenstra, Rinse Klooster, David Maussang-Detaille, Cynthia Timmers, Jonathan Rios-Doria, Horacio Nastri, Jeff Jackson, Patrick Mayes, Chryssa Kanellopoulou
• 5535 · PDF GPRC5D多特异性抗体：针对多发性骨髓瘤的亲和力、跨物种反应性和双/三特异性衔接的工程化设计 GPRC5D multispecific antibodies: Engineering for affinity, cross-species reactivity, and bi/trispecific engagement in multiple myeloma Hayley Roth, Trevor Barnes, Daniel Rogers, Ileine Sanchez, Lewis Joe Stafford, Valerie Firers, Breanna Tyrell, Amelia M. Snyder, Kyle Doolan, Benjamin J. Doranz, Ross Chambers, Joseph B. Rucker
• 5536 · PDF 使用离体循环人全血测定对双特异性抗体进行临床前免疫毒性评估 Preclinical immunotoxicity assessment of bispecific antibodies using an ex vivo circulating human whole blood assay Helena Harlin Laven, Louise Nilsson, Marika Pettersson, Gunilla Törnqvist, Erika Fletcher, Sakthi Ponandai-Srinivasan, Sara Mangsbo, Alexander Kele
• 5537 · PDF 一种半衰期延长的PD-1×VEGFA双特异性抗体在临床前模型中显示出强效的抗肿瘤活性 A half-life extended PD-1×VEGFA bispecific antibody demonstrates potent anti-tumor activity in preclinical models Frank An, Weiqiu Lan, Baihong Liu, Yang Chen, Xi Yang, Jinhua Zhao, Gao An, Yi Yang
• 5538 · PDF 泛alphabeta-T细胞反应性抗TCR VHH双特异性抗体通过新型恒定区靶向显示出强效细胞毒性 Pan-alphabeta-T-cell reactive anti-TCR VHH bispecifics demonstrate potent cytotoxicity through novel constant region targeting Michael B. Battles
• 5539 · PDF BB-202，一种新型抗PD-1/抗VEGF双特异性抗体的抗肿瘤活性 The anti-tumor activity of BB-202, a novel anti-PD-1/anti-VEGF bispecific antibody Hongyan Zhong, Daniel Guo, Phuong Nguyen, Daniel Li, Ming Yang
• 5540 · PDF SCR-M015，一种PD-1/VEGF双特异性抗体在临床前研究中表现出强效的抗肿瘤疗效 SCR-M015, a PD-1/VEGF bispecific antibody exhibits potent anti-tumor efficacy in preclinical studies Qiong Wang, Yayuan Fu, Fengli Shan, Yanqiu Wang, Guimei Yang, Yan Wang, Xiaokang Qin, Renhong Tang
• 5541 · PDF PF-08634404（SSGJ-707）——一种用于癌症治疗的四价PD-1 x VEGF双特异性抗体的表征与功能评价 Characterization and functional evaluation of PF-08634404 (SSGJ-707) a tetravalent PD-1 x VEGF bispecific for the treatment of cancer Ryan A. Heiser, Meghan Zuck, Catalina Sakai, Eliana Moskovitz, Laila Shehata, Markus Carlson, Florian Heinkel, Sherif Abdelhamed, MIchelle Ulrich, Matt Rathgeber, Brian P. O'Connor, Joseph D. Dekker, Haomin Huang, Sharsti Sandall
• 5542 · PDF 新型PD-1xVEGFxIL-2三特异性免疫调节剂具有更优的安全性和更强的疗效 Novel PD-1xVEGFxIL-2 trispecific immune modulator with superior safety and greater efficacy Lei Wu, Mengmeng Sun, Bowei Liao, Shuang Wang, Tengfei Yu, Jijie Gu
• 5543 · PDF 基于机制的细胞检测方法用于筛选和表征双特异性抗体 Mechanism-driven cell-based assays to screen & characterize bi-specific antibodies Venkatesh Chari, Surekha Bonasu, Luhan Yang, Jennifer Lin-Jones, Jane Lamerdin, Alpana Prasad, Gaurav Agrawal
• 5544 5544 类器官-T细胞共培养：一个用于双特异性抗体免疫疗法开发的稳健平台 Organoid-T cell co-cultures: A robust platform for bispecific antibody immunotherapy development Sonia Aristin Revilla, Cesar Oyarce, Sumeyra Mucuk, Javier Frias Aldeguer, Timo Voskuilen, Merel Derksen, Farzin Pourfarzad, Robert G. J. Vries, Sylvia F. Boj
• 5545 · PDF 胶原结合型抗GITR抗体重塑免疫抑制性微环境并延长复发性胶质母细胞瘤的生存期 Collagen-binding anti-GITR antibody reshapes immunosuppressive microenvironment and prolongs survival in recurrent glioblastoma Jun Takei, Chuyi Wang, Ken Furudate, Opeyemi Iwaloye, Lewis Barr, Haruka Ichie, Shunsuke Tsuzuki, Jun Ishihara, Satoru Osuka
• 5546 · PDF 在HNSCC模型中，Rilvegostomig较临床批准的抗PD-1单药疗法引发更强的免疫激活和肿瘤抑制 Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-PD-1 monotherapy in models of HNSCC Jun Ren, Ngan Mitchell, Marie Boutet, Vladimir Roudko, Jeremy Ratiu, Jorge Blando, Sophia Varriano, Elizabeth Galery, Rebecca Halpin, Trevor Connor, Kanam Malhotra, Bartholomew Starich, Jessica Wagner, Yi Luan, Anna Huntley, Joseph Boland, Maurizio Scaltriti, Mark Cobbold, Simon Hollingsworth, Scott Hammond, Doug Palmer, Paul Chariou, Kristen Pollizzi, Daniela Dinulescu
• 5547 · PDF 通过amivantamab同时靶向EGFR和MET增强间皮瘤中的抗体依赖性细胞毒性 Enhancing antibody-dependent cellular cytotoxicityin mesothelioma through concurrent EGFR and MET targeting withamivantamab Shinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, Kuan-Li Wu, Jennifer Ayers-Ringler, Lin Yang, Katherine E. R. Smith, Farhad Kosari, Aaron S. Mansfield
• 5548 · PDF 无偏倚发现用于ALK+非小细胞肺癌的新型巨噬细胞激活型免疫疗法 Unbiased discovery of novel macrophage-activating immunotherapies for ALK+ non-small cell lung cancer Carlota Pages-Geli, Thomas Wienclaw, Juliano Ribeiro, Matheus Silva, Kipp Weiskopf
• 5549 · PDF 新型CTLA4×CD47双特异性抗体HX044治疗窗的非临床建模 Non-clinical modeling the therapeutic window of HX044, a novel CTLA4xCD47 BsAb Hang Ke, Zihan Xu, Tao Yang, Cen Chen, Sheng Gao, Lei Zhang, Faming Zhang, Henry Li
• 5550 · PDF 在MM细胞存在GPRC5D的情况下，Talquetamab改变T细胞转录组 T cell transcriptome is altered by Talquetamab in presence of GPRC5D on MM cells Umair Munawar, Alexander Leipold, Seungbin Han, Silvia Nerreter, Shilpa Kurian, Emma Besant, Nina Rein, Johanna Lehmann, Max Koeppel, Xiang Zhou, Ondrej Slaby, Hermann Einsele, Leo Rasche, Emmanual Saliba, Johannes Waldschmidt, Martin Kortuem
• 5551 · PDF MHC II类靶向免疫疗法治疗胰腺癌 MHC class II targeted immunotherapy in the treatment of pancreatic cancer Reeder Robinson, Leticia Reyes, Samaneh Saberi, Lena Golick, Sandeep Gupta, Michael Ostrowski, Nathan G. Dolloff
• 5552 · PDF MHC II类接合器免疫疗法治疗急性髓系白血病 MHC class II engager immunotherapy for the treatment of acute myeloid leukemia Lena Golick, Reeder Robinson, Leticia Reyes, Sandeep Gupta, Nathan G. Dolloff
• 5553 · PDF 通过双特异性抗体组合实现4-1BB受体的肿瘤选择性激活 Tumor-selective activation of 4-1BB receptor via bispecific antibody combinations Lucie Diby, Pauline Malinge, Valery Moine, Lise Nouveau, Laurence Chatel, Krzysztof Masternak, Limin Shang, Walter Ferlin, Nicolas Fischer, Jose Saro, Mikael Pittet, Vanessa Buatois, Eric Hatterer
• 5554 · PDF 抗人CTLA-4×TIGIT双特异性抗体：一种特异性靶向肿瘤浸润性FOXP3+调节性T细胞的新型免疫疗法 Anti-human CTLA-4×TIGIT bispecific antibody: A novel immunotherapy specifically targeting tumor-infiltrating FOXP3+ regulatory T cells Soojin Ryu, Hee Geon Park, Sang Beom Bang, Ji Hye Nam, Ho Jin Lee, Ju Yeon Seo, Gun Yi Ahn, Myeung Ryun Seo, Sang Moo Lee, Yoon La Choi, Sung Youl Hong, Young Kee Shin

在会议检索中浏览本分会场